QUIA PHARMA AB Logo

QUIA PHARMA AB

Develops medicines using a proprietary drug delivery platform to improve efficacy.

QUIA | ST

Overview

Corporate Details

ISIN(s):
SE0020678159
LEI:
967600JUP7EI6X9D2Z44
Country:
Sweden
Address:
Virdings Allé 32 B, 754 50 Uppsala

Description

QUIA PHARMA AB is a pharmaceutical development company focused on the research, development, and commercialization of medicines. The company's core activity is based on its proprietary and patented drug delivery platform, Uni-Qleaver®. This platform utilizes a unique, releasable pegylation technology designed to improve the properties of drugs by temporarily modifying them. The Uni-Qleaver® technology aims to enhance the therapeutic efficacy and safety profile of pharmaceuticals by extending their duration of action and enabling the release of the active drug in its original, unmodified form. The company applies this platform to develop improved and patentable versions of existing drugs as well as new chemical entities, with a focus on therapeutic areas such as endocrinology and metabolic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all QUIA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QUIA PHARMA AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QUIA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Stayble Therapeutics AB Logo
Develops treatments for chronic pain originating from spinal disc conditions.
Sweden
STABL
STCUBE Logo
Develops immuno-oncology therapies targeting novel immune checkpoints for cancer.
South Korea
052020
StemRIM Inc. Logo
Develops regenerative medicine that uses the body's own stem cells for tissue repair.
Japan
4599
Surrozen, Inc./DE Logo
Develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
United States of America
SRZN
SyntekaBio,Inc. Logo
An AI-driven drug discovery company using supercomputing to accelerate development.
South Korea
226330
Tango Therapeutics, Inc. Logo
A clinical-stage biotech developing precision oncology medicines via synthetic lethality.
United States of America
TNGX
Taysha Gene Therapies, Inc. Logo
Clinical-stage company developing AAV-based gene therapies for severe CNS diseases.
United States of America
TSHA
Tectonic Therapeutic, Inc. Logo
Clinical-stage biotech developing biologics targeting G-Protein Coupled Receptors (GPCRs).
United States of America
TECX
Telomir Pharmaceuticals, Inc. Logo
Pre-clinical pharma company developing a small molecule for aging and chronic disease.
United States of America
TELO
Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing small molecule and cell therapies for cancer.
United States of America
TPST

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.